Does laminectomy alone or laminectomy with fusion lead to better recovery in patients undergoing surgery for degenerative cervical myelopathy from the back?

Submission date 09/02/2022	Recruitment status Recruiting	[X] Prospectively registered [] Protocol
Registration date 11/02/2022	Overall study status Ongoing	 Statistical analysis plan Results
Last Edited 03/03/2025	Condition category Musculoskeletal Diseases	Individual participant data[X] Record updated in last year

Plain English summary of protocol

Background and study aims

Degenerative cervical myelopathy [DCM] is a common condition caused when arthritic changes in the neck compress the spinal cord. It affects up to 2% of adults and causes numb and clumsy hands, imbalance, and bladder problems. Often it continues to worsen with time and left untreated lead to severe disability and paralysis. The only current treatment is surgery, and a number of different operations are used. The aim of surgery is to create space for the spinal cord. Surgery is able to stop further deterioration and lead to some improvements. For people who need DCM surgery from the back of their neck, the pressure on the spinal cord is relieved by removing part of the bone that surrounds the spinal cord called the laminae. This procedure on its own is called a laminectomy. In some cases, metal implants are placed in addition to the laminectomy in order to stiffen the spine. This is called laminectomy and fusion. Both procedures have potential advantages and disadvantages. The aim of this study is to find out whether laminectomy and fusion improves outcomes following surgery for DCM compared to laminectomy alone.

Who can participate?

Patients aged 18 years and over who are scheduled to undergo posterior surgery for DCM with multilevel compression

What does the study involve?

Participants are randomly allocated to treatment with either laminectomy alone or laminectomy and fusion.

What are the possible benefits and risks of participating?

Laminectomy alone is a more straightforward and shorter surgery that does not affect the range of movement in the neck. However, without fusion a change in the alignment of the spine called deformity may develop. Some surgeons believe deformity may affect long-term recovery and may cause greater neck pain for some people. Laminectomy and fusion aims to prevent this deformity but in doing so will greatly reduce the range of movement in the neck (particularly looking over the left or right shoulder). Some people find this a problem for everyday life, such as driving. Furthermore, the insertion of metalwork slightly increases the risks of the surgery, whilst greatly increasing the cost.

Where is the study run from? Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge (UK)

When is the study starting and how long is it expected to run for? April 2020 to November 2028

Who is funding the study? National Institute for Health Research (UK)

Who is the main contact? Mr Stefan Yordanov, s.yordanov@nhs.net

Study website https://polyfix-dcm.com/

Contact information

Type(s) Scientific

Contact name Dr Stefan Yordanov

ORCID ID http://orcid.org/0000-0001-7008-6012

Contact details Cambridge University Hospital Neuroscience Department Hills Rd Cambridge United Kingdom CB2 0QQ +44 (0)7874649949 s.yordanov@nhs.net

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number 297923

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CPMS 50908, IRAS 297923

Study information

Scientific Title

POsterior Laminectomy and FIXation for Degenerative Cervical Myelopathy [POLYFIX-DCM]

Acronym

POLYFIX DCM

Study objectives

Laminectomy and fusion improves outcomes following surgery for multi-level degenerative cervical myelopathy (DCM) when compared to laminectomy alone.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 02/12/2021, HRA and Health and Care Research Wales (HCRW, Castlebridge 4, 15 - 19 Cowbridge Rd E, Cardiff, CF11 9AB, UK; +44 (0)29 2023 0457; hcrw.approvals@wales.nhs.uk), REC ref: 21/YH/0253

Study design Randomized; Interventional; Design type: Treatment, Surgery

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Degenerative cervical myelopathy

Interventions

POLYFIX DCM will be a multi-centre pragmatic, randomised trial, with blinded outcome assessment, aiming to determine the comparative clinical- and cost-effectiveness of

decompression and fusion, with decompression alone for multi-level DCM treated posteriorly. Due to the nature of the trial, the local clinical teams, patients and carers cannot be blinded to allocation. However, by employing centralised telephone follow-up, a blinded assessment of the primary outcome can be performed. The trial will be preceded by an internal pilot in order to confirm recruitment, randomisation, treatment, and follow-up assessments.

POLYFIX DCM will address the following hypothesis: 'Laminectomy and fusion improves outcomes following surgery for multi-level degenerative cervical myelopathy when compared to laminectomy alone.'

The primary outcome measure for this trial is the modified Japanese Orthopaedic Association Score (mJOA). The mJOA was therefore selected as the single primary end-point, on the basis: 1. The recovery priorities for patients are pain, hand and walking function

2. The mJOA is the international standard, and most validated measure for the assessment of neuromuscular function in DCM and has been the primary endpoint for most leading trials. It primarily evaluates motor dysfunction in the upper and lower extremities but also altered sensation (including pain) to the hand(s) and sphincter dysfunction

3. Pain is a complex experience, and a single pain outcome tool has not been specifically validated for use in DCM

4. The NIHR HTA (funder) favoured a single primary endpoint (vs co-primary endpoint)

5. Although traditionally a clinician-administered score, a version has now been developed for use remotely, potentially more conducive to current NHS practice due to the COVID-19 pandemic

The researchers plan to include 394 participants in this trial from approximately 20-30 sites in the UK and 5-10 sites internationally. In anticipation of requirements to optimise recruitment processes they propose initially three patient focus groups of 3-6 people (one within the pilot phase, two within the substantive phase) conducted online using Zoom or an equivalent videoconferencing system. These workshops will focus on understanding individual experiences and are not designed to change their opinions. Participation will be voluntary.

Potentially eligible patients with DCM will be approached by a delegated member of the local trial team and given a participant information sheet to read in their own time. If they decide to participate in the trial, they will undergo a screening assessment to confirm their eligibility for the trial. Screening assessments will assess the following at an outpatient appointment: age, mJOA, planned surgical intervention, DCM characteristics (symptoms, length of DCM symptoms), MRI image findings (number of cervical spine levels for treatment) and a neurological examination. Following screening, eligible subjects will be randomised by an online randomisation system in a 1:1 ratio to treatment with either laminectomy alone or laminectomy and fusion. They will then be given a unique trial ID number. Each patient has the right to withdraw from the trial at any time.

The following baseline assessments will then take place: weight (kg), smoking status, psychiatric comorbidities, impaired gait, medical history (comorbidities), medication history, mJOA assessment, SF36v2 (quality of life) score (physical component score and mental component score), EQ5D-5L, patient health questionnaire (PHQ9), Generalised Anxiety Disorder Questionnaire (GAD7), Neck Disability Index (NDI), Brief Pain Inventory (BPI), Douleur Neuropathique 4 (DN4), Michigan Body Map (pain location), cervical x-rays (deformity, auto-fusion, movement), Myelopathy.org symptom inventory, (Updated) Charleston Comorbidity Index, healthcare resource use questionnaire.

The following intraoperative assessments will take place when the patient undergoes their surgical treatment: operation title, levels treated, American Society Anaesthesiology (ASA)

grade, operation duration, estimated blood loss, intraoperative complications, use of intraoperative navigation or intraoperative neuromonitoring (neurophysiology), nature of Inserted Metalwork, if applicable (number/brand) and use of synthetic products to support fusion. On discharge, the following will be assessed: length of stay and ward type, complications, other adverse events (e.g. requirement for blood transfusion) and change in medication.

Postoperatively, participants are to be reviewed at 6-, 12- and 24-months post-surgery for assessments. At each of these reviews, the following will be assessed: mJOA, SF36v2 (quality of life) Score, EQ5D-5L, Neck Disability Index (NDI), Brief Pain Inventory (BPI), Douleur Neuropathique 4(DN4), Michigan Body Map (Pain Location), complications (including surgical site infection, wound breakdown, instrument failure), adverse events, cervical x-rays (deformity, fusion, movement), Myelopathy.org symptom inventory, change in medication and healthcare resource use questionnaire.

Outcomes are largely centralised, and either conducted by the patient, or an assessor blinded to their trial arm. The only pre-defined requirement for local sites is to arrange the cervical spine x-rays.

Additionally, participants will be informed of an option to measure CarerQOL at baseline. As a chronic disease with a significant disability, patients are often dependent to some degree on those around them, which in turn affect their carers' quality of life. Contact details will be provided should the participant, or their informal carer(s) have follow up questions for the investigator team. Informal carers consenting to participate will be sent a CarerQOL to complete at baseline, discharge from hospital, 6, 12 and 24 months after surgery.

Trial participation will end 24 months post-surgery for each participant (unless consent has been given, and funding secured, for extended follow up). Following trial completion, patients will return to routine care as per their local centre protocols.

Intervention Type

Procedure/Surgery

Primary outcome measure

Neurological outcome measured using the Modified Japanese Orthopaedic Association score (mJOA) at 24 months

Secondary outcome measures

1. Pain measured using the VAS pain at 6, 12 and 24 months

2. Quality of life measured using the SF36v2 Score (Physical Component Score, Mental Component Score and Bodily Pain) at 6, 12 and 24 months

- 3. Quality of life measured using the EQ5D-5L at 6, 12 and 24 months
- 4. Pain/neck disability measured using the Neck Disability Index (NDI) at 6, 12 and 24 months
- 5. Pain/neck disability measured using the Brief Pain Inventory (BPI) at 6, 12 and 24 months
- 6. Pain measured using the Douleur Neuropathique 4 (DN4) at 6, 12 and 24 months
- 7. Pain measured using the Michigan Body Map (Pain Location) at 6, 12 and 24 months

8. Procedural complications, including intraoperative blood loss, dural tear, surgical site infection, wound breakdown and instrument failure, measured using case notes review at the time of surgery/post-operative period

9. Adverse events measured using patient interview, clinic and telephone visits at 6, 12 and 24 months

10. Length of hospital stay, measured using hospital electronic patient records (EPR) at discharge

11. Length of operation, measured using hospital EPR post-operatively

12. Discharge destination, measured using hospital EPR at time of discharge.

13. Alignment (C2–7 lordosis, C2–7 sagittal vertical axis and T1 slope), fusion and movement assessed using cervical, dynamic x-rays at 6, 12 and 24 months

14. Quality of life measured using the Myelopathy.org symptom inventory at 6, 12 and 24 months

Overall study start date

10/04/2020

Completion date

01/11/2028

Eligibility

Key inclusion criteria

1. Have given written informed consent to participate

- 2. Be aged 18 years and over
- 3. Have a diagnosis of DCM, based on established criteria
- 4. Be scheduled for posterior surgery, involving two or more consecutive laminae
- 5. Be able to read and understand English

Participant type(s) Patient

Age group Adult

Lower age limit 18 Years

Sex

Both

Target number of participants Planned Sample Size: 394; UK Sample Size: 394

Key exclusion criteria

Mild and non-progressive DCM (defined as stable mJOA score >16 at two consecutive time points)
 Presentation in the context of acute trauma (e.g. central cord syndrome or spinal cord injury)

Date of first enrolment 01/03/2022

Date of final enrolment 01/05/2026

Locations

Countries of recruitment

England

Scotland

United Kingdom

Wales

Study participating centre Cambridge University Hospitals NHS Foundation Trust Cambridge Biomedical Campus Hills Road Cambridge United Kingdom CB2 0QQ

Study participating centre

The Walton Centre NHS Foundation Trust Lower Lane Liverpool United Kingdom L9 7LJ

Study participating centre

South Tyneside and Sunderland NHS Foundation Trust Sunderland Royal Hospital Kayll Road Sunderland United Kingdom SR4 7TP

Study participating centre

The Newcastle upon Tyne Hospitals NHS Foundation Trust Freeman Hospital Freeman Road High Heaton Newcastle upon Tyne United Kingdom NE7 7DN

Study participating centre

Sheffield Teaching Hospitals NHS Foundation Trust

Northern General Hospital Herries Road Sheffield United Kingdom S5 7AU

Study participating centre NHS Ipswich and East Suffolk CCG Endeavour House Russell Road Ipswich United Kingdom

IP1 2BX

Study participating centre University Hospitals of Derby and Burton NHS Foundation Trust Royal Derby Hospital Uttoxeter Road Derby United Kingdom DE22 3NE

Study participating centre Brighton and Sussex University Hospitals NHS Trust Royal Sussex County Hospital Eastern Road Brighton United Kingdom BN2 5BE

Study participating centre NHS Lothian Waverley Gate 2-4 Waterloo Place Edinburgh United Kingdom EH1 3EG

Study participating centre

Cardiff & Vale University Lhb

Woodland House Maes-y-coed Road Cardiff United Kingdom CF14 4HH

Study participating centre

NHS Greater Preston CCG

Chorley House Lancashire Enterprise Business Park Centurion Way Leyland United Kingdom PR26 6TT

Study participating centre

King's College Hospital NHS Foundation Trust Denmark Hill London United Kingdom SE5 9RS

Study participating centre

University College London Hospitals NHS Foundation Trust 250 Euston Road London United Kingdom NW1 2PG

Study participating centre Barts Health NHS Trust The Royal London Hospital 80 Newark Street London

United Kingdom E1 2ES

Study participating centre St George's University Hospitals NHS Foundation Trust St George's Hospital

Blackshaw Road Tooting London United Kingdom SW17 0QT

Study participating centre Nottingham University Hospitals NHS Trust Trust Headquarters Queens Medical Centre Derby Road Nottingham United Kingdom NG7 2UH

Study participating centre Royal National Orthopaedic Hospital NHS Trust Brockley Hill Stanmore United Kingdom HA7 4LP

Study participating centre Leeds Teaching Hospitals NHS Trust St. James's University Hospital Beckett Street Leeds United Kingdom LS9 7TF

Sponsor information

Organisation Cambridge University Hospitals NHS Foundation Trust

Sponsor details Cambridge Biomedical Campus Hills Road Cambridge England United Kingdom CB2 0QQ +44 (0)1223 348490 research@addenbrookes.nhs.uk

Sponsor type Hospital/treatment centre

Website http://www.cuh.org.uk/

ROR https://ror.org/04v54gj93

Funder(s)

Funder type Government

Funder Name NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR131243

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

01/11/2028

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No